HAPPE Spine has announced two new additions to its board of directors following a US$3.35 million Series A financing round, the funds of which will be used to help launch an interbody spinal fusion implant, with a focus on completing final regulatory testing and obtaining 510(k) approval.
The five-member board of directors now includes Steven Foster, who has over thirty years of marketing, sales, operations, and general management experience in the medical device space, primarily in spine. He currently serves as CEO and president of Tenon Medical.
“I am excited by technologies that solve real problems. The HAPPE material platform overcomes the limitations of both titanium and PEEK in interbody spinal fusion. I couldn’t be more excited to work with the HAPPE team,” said Foster.
Joining him on the board is Andrew Iott who brings with him twenty years of experience in medical device product development and commercialisation, in particular spinal implants. He is a co-founder of Globus Medical and sits on a various boards.
“I’m honoured to join the board of HAPPE Spine. HAPPE’s porous and bioactive PEEK technology is a critical advancement in materials for spinal implants. I’m excited to see the benefits that HAPPE’s products will bring to orthopaedic procedures,” he said.
The remaining seats on the board are filled by founder and CEO, Ryan Roeder, Todd Smullen (Praxa Medical), and Doug Snell (Genesis Innovation Group).